Formycon

Formycon Enterprise Value

The Enterprise Value (EV) of Formycon (FYB.DE) as of Nov 19, 2026 is 361.33 M EUR. In the previous year, Enterprise Value (EV) was 389.37 M EUR — a change of -7.20% (lower).

Enterprise Value

361.33 MEUR

YoY

-7.20%

Last updated:

Enterprise Value (EV) of Formycon is 2025 361.33 M EUR. Enterprise Value (EV) of Formycon was 2024 389.37 M EUR. It decreases by -7.20% lower compared to the previous year.

The Formycon Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
413.28 M EUR
Jan 1, 2019
398.50 M EUR
Jan 1, 2020
384.33 M EUR
Jan 1, 2021
400.72 M EUR
Jan 1, 2022
460.10 M EUR
Jan 1, 2023
423.06 M EUR
Jan 1, 2024
389.37 M EUR
Jan 1, 2025
361.33 M EUR
The Formycon Enterprise Value history
YEAREnterprise ValueYoY
361.33 MEUR-7.20%
389.37 MEUR-7.96%
423.06 MEUR-8.05%
460.10 MEUR+14.82%
400.72 MEUR+4.26%
384.33 MEUR-3.55%
398.50 MEUR-3.58%
413.28 MEUR+2.01%
405.14 MEUR-2.99%
417.62 MEUR-0.56%
419.99 MEUR-0.09%
420.35 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Formycon Stock analysis

What does Formycon do? Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Formycon stock

Enterprise Value (EV) of Formycon is 361.33 M EUR in 2025.

Enterprise Value (EV) of Formycon changed from 389.37 M EUR to 361.33 M EUR, representing a -7.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) Formycon since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s EUR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' EUR varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s Formycon with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Formycon

All Key Metrics — Formycon